Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jay S. Loeffler(Brigham and Women's Hospital), Dan G. Duda(Harvard University), Jeffrey W. Clark(Massachusetts General Hospital)
Cited by 1,040
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05
|International Journal of Radiation Oncology*Biology*Physics|2000|1.6k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k